- Molecular NameModafinil
- SynonymModafinil [USAN:INN]; Modafinilo [Spanish]; Modafinilum [Latin]; Moderateafinil
- Weight273.356
- Drugbank_IDDB00745
- ACS_NO68693-11-8
- Show 3D model
- LogP (experiment)1.736
- LogP (predicted, AB/LogP v2.0)1.99
- pkaN/A
- LogD (pH=7, predicted)1.99
- Solubility (experiment)Slightly soluble
- LogS (predicted, ACD/Labs)(ph=7)-2.47
- LogSw (predicted, AB/LogsW2.0)0.22
- Sw (mg/ml) (predicted, ACD/Labs)0.93
- No.of HBond Donors2
- No.of HBond Acceptors3
- No.of Rotatable Bonds5
- TPSA79.37
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn analeptic drug manufactured by Cephalon, and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy, shift work sleep disorder, and excessive daytime sleepiness associated with obstructive sleep apnea.
- Absorption_value80.0
- Absorption (description)It may also induce P-glycoprotein, which may affect drugs transported by Pgp, such as digoxin.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding60.0
- Volume of distribution (VD)0.9 L/kg or 80 L
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmModafinil induces the cytochrome P450 enzymes CYP1A2, CYP2B6 and CYP3A4, as well as inhibiting CYP2C9 and CYP2C19 in vitro. It may also induce P-glycoprotein, which may affect drugs transported by Pgp, such as digoxin. It is metabolized in the liver, and its inactive metabolite is excreted in the urine.
- Half life10 to 15 h.
- ExcretionUrinary excretion of the unchanged drug ranges from 0% to as high as 18.7%, depending on various factors.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A